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Autism spectrumdisorders (ASD) and schizophrenia are neurodevelopmental disorders for which recent evidence indicates an important
etiologic role for rare copy number variants (CNVs) and suggests common genetic mechanisms. We performed cytogenomic array
analysis in a discovery sample of patients with neurodevelopmental disorders referred for clinical testing. We detected a recurrent
1.4 Mb deletion at 17q12, which harbors HNF1B, the gene responsible for renal cysts and diabetes syndrome (RCAD), in 18/15,749
patients, including several with ASD, but 0/4,519 controls. We identified additional shared phenotypic features among nine patients
available for clinical assessment, including macrocephaly, characteristic facial features, renal anomalies, and neurocognitive impair-
ments. In a large follow-up sample, the same deletion was identified in 2/1,182 ASD/neurocognitive impairment and in 4/6,340 schizo-
phrenia patients, but in 0/47,929 controls (corrected p ¼ 7.37 3 105). These data demonstrate that deletion 17q12 is a recurrent,
pathogenic CNV that confers a very high risk for ASD and schizophrenia and show that one or more of the 15 genes in the deleted
interval is dosage sensitive and essential for normal brain development and function. In addition, the phenotypic features of patients
with this CNV are consistent with a contiguous gene syndrome that extends beyond RCAD, which is caused by HNF1Bmutations only.Introduction
Autism is the most severe end of a spectrum of neurodeve-
lopmental conditions collectively known as autism spec-
trum disorders (ASD [MIM 209850]), which also include
Asperger syndrome and pervasive developmental disorder
not otherwise specified (PDD-NOS). Autism is character-
ized by impairments in social interaction, deficits in
communication, and repetitive and stereotypical patterns
of interests and behavior that manifest before 3 years of
age. Affecting males four times as often as females, the
prevalence of autism is considered to be 1 in 500 individ-
uals, rising to 1 in 110 when all ASD are included.1
Schizophrenia (MIM 181500) is also a neurodevelop-
mental disorder involving a broad range of social, cogni-
tive, and perceptual functions. With a prevalence of 1 in
100 to 1 in 200, the disorder typically comes to clinical
attention when frank ‘‘positive’’ psychotic symptoms
(hallucinations, delusions, disordered thinking, and
bizarre behavior) or ‘‘negative’’ symptoms (profound social1Department of Human Genetics, Emory University School of Medicine, Atl
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adolescence or early adulthood. Males are affected 1.4
times as often as females, and the age of onset is typically
somewhat earlier, and course of illness more severe, in
males.2
The genetic overlap between ASD and schizophrenia has
been the focus of several recent studies. Both conditions
are strongly genetic, as evidenced by a heritability higher
than 80% for each of these disorders.3 Furthermore,
despite the etiological and phenotypic variability of autism
and schizophrenia, the same structural variants are being
identified in both diagnoses.3,4 However, none of the indi-
vidual mutations and copy number variants (CNVs) iden-
tified to date in both disorders account for more than 1%
to 2% of the cases.5,6 This substantial etiologic heteroge-
neity resembles that observed in intellectual disability,
where many different rare mutations account for the
majority of cases with a known genetic cause.7
One approach to addressing this heterogeneity is to
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or overlapping CNVs to identify genotype-phenotype
correlations. Although individually rare, these genomic
imbalances are invaluable tools for uncovering new candi-
date genes and shared molecular pathways that could
provide a better understanding of the pathophysiology of
neurodevelopmental disorders, such as ASD and schizo-
phrenia.8,9
Recurrent CNVs, which occur through nonallelic homol-
ogous recombinationmediated by segmental duplications,
are frequently identified via clinical genetic testing.10 The
expansion of cytogenomic array technologies has led to
greater recognition of this type of imbalance over the past
few years, and in turn the discovery of several new genomic
disorders caused by CNVs that were previously undetected,
with ASD or schizophrenia as part of the phenotype. Recur-
rentCNVs associatedwithbothdiagnoses includedeletions
in 1q21 (MIM 612474),11,12 3q29 (MIM 609425),13,14
15q13.3 (MIM 612001),12,15,16 and 22q11.2 (MIM
188400),12,17 as well as duplications in 16p11.2 (MIM
611913)18,19 and 16p13.1.20,21 As more arrays are per-
formed and collaboration among genetic laboratories is
fostered,moreCNVs that cause or predispose to neurodeve-
lopmental or psychiatric disorders will be identified.
Here we describe the association between a recurrent
deletion at 17q12, which harbors HNF1B (hepatocyte
nuclear factor 1 homeobox B [MIM 189907]), the gene
responsible for renal cysts and diabetes syndrome (RCAD
[MIM 137920]), and both ASD and schizophrenia, giving
further support to a shared genetic etiology in a subset of
cases and pointing to one or more of the 15 genes in the
deleted interval as strong candidates for neurodevelop-
mental and psychiatric disorders.Subjects and Methods
International Standards for Cytogenomic Arrays
Consortium
Subjects
We used whole-genome cytogenomic array analysis to search for
pathogenic CNVs in a discovery sample from the International
Standards for Cytogenomic Arrays (ISCA) Consortium, an interna-
tional collaboration among clinical cytogenomic laboratories
whose purpose is to standardize cytogenomic array testing and
facilitate public data sharing.22 We assessed 15,749 patients
referred for clinical genetic testing because of ASD, developmental
delay, and/or intellectual disability. There was a referring diagnosis
of ASD in approximately 15%–20% of the cases, in line with
reports on similar populations.22 We analyzed data from seven
ISCA laboratories: Emory University, GeneDx, University of Ne-
braska Medical Center, ARUP Laboratories, Mayo Clinic, Michigan
Medical Genetics Laboratories, and Wessex Regional Genetics
Laboratory. Research-based informed consent was not required
because results were anonymous. We carried out additional clin-
ical assessments on nine patients with 17q12 deletions identified
by Emory University and GeneDx, from whom we obtained
written informed consent. All procedures followed are in accor-
dance with the ethical standards of the Institutional Review Board
at Emory University.The AmericanCytogenomic Array and Confirmation of Findings
We performed cytogenomic array testing according to the
manufacturer’s protocol, via custom-designed oligonucleotide
arrays on 4344K, 23105K, and 43180K platforms (Agilent Tech-
nologies, Santa Clara, CA). These designs combine both backbone
coverage across the whole genome (probes spaced every 25–75 kb,
depending on the design) and targeted coverage of clinically
relevant regions (a minimum of 10–20 probes per gene or region,
depending on the design), as described elsewhere.23
We used fluorescence in situ hybridization (FISH) and quantita-
tive PCR (qPCR) to confirm all 17q12 deletions and to test for
parental inheritance. For FISH analyses, we used homebrew FISH
probes (BACs; bacterial artificial chromosome clones) as previ-
ously described.23 For confirmation by qPCR, we assessed gene
dosage for HNF1B by genomic real-time PCR by using TaqMan
probe chemistry and the Universal ProbeLibrary system (Roche
Applied Science, Indianapolis, IN) with SOD1 (MIM 147450) as
a control.
Clinical Assessments
All nine patients for whom we obtained written informed
consent had a comprehensive medical and behavioral evaluation,
performed by a clinical geneticist and either a developmental
pediatrician, a psychiatrist, or a clinical psychologist. Previous
medical records from all nine patients were reviewed. We used
DSM-IV criteria to assess for ASD. When possible, additional
supporting tests were performed, including the Autism Diagnostic
Interview-Revised (ADI-R), the Autism Diagnostic Observation
Schedule (ADOS), the Childhood Autism Rating Scale (CARS),
and the Quantitative Checklist for Autism in Toddlers (Q-CHAT).
SGENE Consortium, deCODEGenetics, and GeneSTAR
Subjects
We included 4,173 patients with schizophrenia, 376 patients with
ASD and/or neurocognitive impairment, and 43,899 ethnically
matched control individuals. All subjects gave written informed
consent. The populations of patients and controls we analyzed
and their sources are summarized below (Table 2).
Iceland
The Icelandic sample consisted of 625 cases with schizophrenia,
376 cases with developmental delay (autistic spectrum disorders,
intellectual disability, or slow expressive language development
[SELD]), and 33,645 controls. Patients and controls were all
Icelandic and were recruited from all over Iceland. Diagnoses
were assigned according to Research Diagnostic Criteria (RDC24)
through the use of the Schedule for Affective Disorders and Schizo-
phrenia Lifetime Version (SADS-L25). The 33,645 controls were
recruited as a part of various genetic programs at deCODE and
were not screened for psychiatric disorders. Subjects with known
attention deficit and hyperactive disorder, dyslexia, and bipolar
were omitted from the control group. Furthermore, parents of
subjects with schizophrenia and developmental delay were also
omitted from the control group. Apart from this, the control group
is in line with what has been reported previously.26 All subjects
gave a written informed consent for their participation.
Finland
The Finnish genome-wide typed sample consisted of 187 schizo-
phrenia patients and 195 controls that had no medical history
of schizophrenia. The controls were selected from among partici-
pants of the Health 2000 survey27,28 and were matched with the
cases with regard to age and sex. The schizophrenia patients
were drawn from a nationwide collection of families with schizo-
phrenia spectrum disorders. Two independent psychiatrists blindJournal of Human Genetics 87, 618–630, November 12, 2010 619
to family structures made a consensus diagnosis to give
best-estimate lifetime diagnoses according to the criteria of
Diagnostic and Statistical Manual of Mental Disorders, 4th edition
(DSM-IV).29–31 Approximately half of the sample originated from
an internal isolate of Finland (Kuusamo-Finland A) having a
3.0% age-corrected lifetime risk for schizophrenia compared to
1.1% in the general population.30
Scotland
The Scottish samplewas comprised of 648 schizophrenia cases and
663 controls. All participants self-identified as born in the British
Isles (95% in Scotland). All cases met DSM-IV and International
Classification of Diseases, 10th revision (ICD-10) criteria for schizo-
phrenia. Diagnosis wasmade by the Operational Criteria Checklist
(OPCRIT32). Controls were volunteers recruited through general
practices in Scotland. Practice lists were screened for potentially
suitable volunteers by age and sex and by exclusion of subjects
with major mental illness or use of antipsychotic medication.
England
Samples from the English subjects (n ¼ 91) were drawn from the
Maudsley Family Study of psychosis,33 the psychosis twin study,34
and the genetics and psychosis (GAP) study for which cases were
derived from the Camberwell case register.35 All controls were
unrelated European whites (n ¼ 83). Patients were interviewed
with the SADS-L24 or the Item Group Checklist (IGC) of the
Schedule for Clinical Assessment in Neuropsychiatry (SCAN36)
and only patients with an ICD-10 research diagnosis of schizo-
phrenia were finally included as cases. The study received approval
from the Ethics Committee of South London and the Maudsley
Trust, and after complete description of the study to the partici-
pants, written informed consent was obtained.
Italy
Diagnosis of the 84 Italian subjects was identical to that for the
GAP sample (see England), via the IGC. Patients with a diagnosis
of psychotic disorders (ICD-10, F20-F25) attending the South
Verona CMHS were identified from the South Verona Psychiatric
Case Register, and cases with ICD-10 research diagnosis of
schizophrenia were finally included. The controls (n ¼ 86) were
unrelated volunteers randomly selected from the general popula-
tion of South Verona. The study received ethical approval and after
complete description of the study to the participants, written
informed consent was obtained.
Germany
The German sample consisted of 1086 schizophrenia cases and
1435 controls. All cases and controls were whites of German
descent. All cases diagnosed according to DSM-IV criteria based
on SCID,37 SADS-L,24 and OPCRIT. The controls were unrelated
volunteers from the general population. Ethical approval was
obtained from the local Ethics Committees, and all participants
gave written informed consent.
The Netherlands
The Dutch sample consisted of 614 patients and 469 controls
obtained from the University Medical Center Utrecht and an
additional 3218 control individuals collected by the Radboud
UniversityNijmegenMedicalCentre (RUNMC) in theNetherlands.
In-patients and out-patients were recruited from different
psychiatric hospitals and institutions throughout theNetherlands,
coordinated via academic hospitals in Amsterdam, Groningen,
Maastricht, andUtrecht. Detailedmedical and psychiatric histories
were collected, including theComprehensive Assessment of Symp-
toms and History (CASH), an instrument for assessing diagnosis
and psychopathology. Only patients with a DSM-IV diagnosis of
schizophrenia were included as cases. The University Medical620 The American Journal of Human Genetics 87, 618–630, NovembCenter Utrecht controls were volunteers and were free of any
psychiatric history. The RUNMC controls were collected as cancer
and control samples. As for SGENE-plus, STRUCTURE runs were
carried out on the genome-wide typed samples, and individuals
with less than 90% estimated European white ancestry were
removed. Ethical approval was obtained from the local Ethics
Committees (including the Institutional Review Board of Radboud
University) and all participants gave written informed consent.
Denmark
The Danish sample included 565 patients who had been recruited
to the Danish Psychiatric Biobank from the psychiatric depart-
ments at the six hospitals in the Copenhagen region. All patients
had been clinically diagnosed with schizophrenia according to
ICD-10 (F20) without ever having received a diagnosis of mania
or bipolar illness (F30-31). An experienced research and consultant
psychiatrist verified high reliability of the clinical diagnoses via
OPCRIT. Healthy control subjects (n ¼ 888) were recruited
through the Danish Blood Donor Corps in the Copenhagen
area. Apparent behavioral abnormality was an exclusion criterion
and all individuals stated that they felt completely healthy and
were able to discuss health-related issues with a physician. An
additional 493 population control samples from the Copenhagen
area were recruited by the Danish Headache Center. The Danish
Scientific Committees and the Danish Data Protection Agency
approved the study and all the patients had given written
informed consent prior to inclusion into the project.
Norway
The Norwegian sample included 274 schizophrenia patients who
had been recruited to the TOP (Tematisk omra˚de psykoser) study
at Oslo University Hospital-Ulleval from all the psychiatric hospi-
tals in the Oslo area. The patients were diagnosed according to the
SCID as having schizophrenia. The healthy control subjects (n ¼
371) were randomly selected from statistical records of persons
from the same catchment area as the patient groups. Only subjects
born in Norway, all of European white origin, were contacted by
letter and invited to participate. All subjects had given written
informed consent prior to inclusion into the project and the
Norwegian Scientific-Ethical Committee and the Norwegian
Data Protection Agency approved the study.
GeneSTAR
We analyzed copy number data from 3241 control individuals
from USA participating in genetic studies carried out by deCODE
genetics (2021 whites and 1220 African Americans).
Genetic Analyses
All samples, except the Norwegian, were genotyped with Illumina
(Illumina Inc., San Diego, CA) SNP microarrays (317K, 370K,
550K, 1M) as previously described.38 PennCNV39 was used for
CNV detection, and only the subset of SNPs present on all the
Illumina microarrays used in this study were taken into account
for CNV detection (a total of 305,381 SNPs). In this subset of
SNPs, 137 are within the 17q12 deletion. The Norwegian sample
was genotyped via the Affymetrix 6.0 SNP microarrays (Affyme-
trix, Santa Clara, CA). PennCNV39 was used to analyze copy
number variants in the full Affymetrix array and then the 17q12
region was manually inspected for large deletions.Simons Foundation Autism Research Initiative
Simplex Collection
Subjects
Genetic dosage information was available for 806 individuals with
ASD (698males and 108 females). All the patients came fromUSA,er 12, 2010
from families with a single individual affected with ASD. Addition-
ally, the 1612 unaffected parents of these individuals were
included as control samples, as well as matched control individ-
uals from GeneSTAR. All subjects gave written informed consent.
Genetic Analyses
Samples were run on Illumina Human 1M and Human 1M Duo
microarrays (Illumina Inc.) and analyzed by the SSC (Simons
Foundation Autism Research Initiative Simplex Collection)
Genetics Consortium (SSCGC). The microarray data were reclus-
tered in Beadstudio (Illumina Inc.) against 200 unaffected parents
from the SSC; genotypes and intensity data were exported for anal-
ysis. Reported family structure was checked by assessing gender,
mendelian errors, and identity-by-descent via PLINK v1.06.40
CNV detection and quality control was performed with CNVi-
sion v1.0, a CNVanalysis package that runs andmerges the results
from three detection algorithms: PennCNV,39 QuantiSNP v1.1,41
and GNOSIS (a CNV detection algorithm within CNVision). The
inheritance of CNVs was determined by comparing CNVs in
offspring to the CNVs in their parents and re-examining parental
genotypes and intensity data within each detected CNV for
evidence of an inherited CNV.
Genetic Association Information Network Collection
Subjects and Genetic Analyses
We analyzed raw data for CNV analysis, based on the Affymetrix
6.0 array platform, from 2167 schizophrenia cases and 2418
controls. Normalization and log ratio data calculation was ob-
tained with the Affymetrix power tools (APT) software (Affyme-
trix). Log2 ratio data for chromosome 17 was extracted and
analyzed with the BEAST algorithm (A.S. Allen, M.I. Ikeda, I.
Morna, J.G.M., G.A. Satten, and S.T.W., unpublished data). All
subjects gave written informed consent.
Statistical Analyses
All p values and odds ratios were calculated via Fisher’s exact test in
R. We used the Cochran-Mantel-Haenszel model42 to correct for
ethnic origin when possible.Results
Discovery Sample
17q12 Deletion Identified in a Clinical Testing Setting
We identified 18 patients with the same 17q12 deletion
(13 males and 5 females) out of the 15,749 we assessed
within the ISCA consortium (dbVar; accession number
NSTD37). We confirmed all 18 deletions with FISH or
qPCR. This CNV was absent from 4519 previously pub-
lished control individuals43,44 and from the Database of
Genomic Variants,45 which serves as a repository for
CNVs in several control populations. We found the recip-
rocal 17q12 duplication, which has been associated with
intellectual disability and epilepsy,46,47 in 21 cases and 2
controls within the same population. Additionally, this
duplication was inherited in 7 out of the 11 cases for
whom we had parental copy number information. For
this study, we chose to focus on the 17q12 deletion given
that among this discovery sample, we observed an empir-
ical association between this recurrent CNV and autism
as a referral diagnosis (4 out of the 16 patients with refer-The Americanring diagnosis information were sent for ASD). To confirm
this observation and to comprehensively assess the clinical
spectrum associated with this CNV, we obtained additional
clinical information on eight individuals and the affected
mother of one of them, who also had the 17q12 deletion.
We performed high-resolution cytogenomic array on these
nine patients (eight probands and the affected mother) by
using a custom 180K array design to standardize the array
results of these patients and to exclude the presence of
smaller genomic anomalies elsewhere. We confirmed
a 1.4 Mb region deleted in all patients (Figure 1)
(chr17:31,893,783-33,277,865; hg18 genome assembly)
containing 15 genes (AATF [MIM 608463], ACACA [MIM
200350], C17orf78, DDX52 [MIM 612500], DHRS11,
DUSP14 [MIM 606618], GGNBP2 [MIM 612275], HNF1B,
LHX1 [MIM 601999], MRM1, MYO19, PIGW [MIM
610275], SYNRG [MIM 607291], TADA2A [MIM 602276],
ZNHIT3 [MIM 604500]) consistent with previous reports.46
The breakpoints of each of the deletions lie within a cluster
of highly homologous segmental duplications that range
from 300 kilobases (kb) to 400 kb in size and vary in
copy number, which hampered the precise identification
of the boundaries of the deletion. At the 75 kb backbone
resolution of our genome-wide 180K array, we detected
no other pathogenic genomic rearrangements22 in any of
these individuals. The deletion was de novo in seven out
of the eight cases we studied in detail. In one case, the dele-
tion was inherited from an affected mother who had poly-
cystic kidneys (MIM 173900) and diabetes mellitus (MIM
125853), features previously observed in patients with
this CNV.46 Remarkably, she also had a long history of
bipolar disorder (MIM 125480).
These nine patients shared a number of consistent
phenotypic features (Table 1 and Figure 2); a more exten-
sive clinical comparative description of patients is available
online (Table S1). Macrocephaly, defined for this study as
head circumference over the 90th percentile, or relative
macrocephaly and dolichocephaly were observed in most
of the patients. Similar mild facial dysmorphic features
were present in all cases (Figure 2). Genitourinary tract
anomalies were present in most of the probands and
included prenatal echogenic renal calyces, prenatal hydro-
nephrosis, unilateral and bilateral cystic kidneys, urethral
stenosis, and uterus didelphis. Only the eldest of the
patients, a 37-year-old woman, had diabetes. In addition,
recurrent infections of the ear, upper respiratory system,
and urinary tract, scoliosis, and hypermetropia were each
observed in more than two cases. One of the patients
(Case 6) had short stature.
Mild to moderate neurocognitive impairment was
present in most patients, primarily affecting speech. We
observed different degrees of difficulties in sensory integra-
tion and motor skills, specifically regarding coordination
and motor tasks. Remarkably, autism or autistic features
were present in all six male patients. Four of them met
DSM-IV and/or ADI-ADOS diagnostic criteria for autism,
and the other two had autistic behaviors but did not meetJournal of Human Genetics 87, 618–630, November 12, 2010 621
Figure 1. 17q12 Region
Chromosome 17 schematic showing a close-up of 17q11.2-17q12, including selected genes and segmental duplications in the region,
along with the results of four different autism linkage studies51–54 and one association study on male-only autism families55 (black
squares [in Stone et al.,54 black squares correspond to markers flanking the linkage peak and are connected by a dotted horizontal black
line]). The recurrent 17q12 deletion found in our patients is depicted as a horizontal blue line, flanked by segmental duplications (blue
shaded rectangles). The 180K cytogenomic array results of one of the patients are shown below.the threshold for a formal diagnosis of autism. Case 6 was
too young at the time of assessment for a conclusive diag-
nosis, though he had been previously referred for evalua-
tion because of delayed development and autistic features,
including stereotypic behaviors and relative deficits in
social responsivity and joint attention. Case 9 did not
meet formal criteria for autism, but he presented with
autistic features, comprising excessive insistence on per-
forming tasks to perfection and difficulties in disengaging
from those tasks, emotional irritability, and unusual affect.
Difficulties in social skills were present but had a late onset,
on the background of nonverbal learning disability. Addi-
tionally, he had marked anxiety, which was seen in most
of the patients as well. Obsessive-compulsive behaviors
and prominent anxiety were seen along with the autism
diagnosis in most of these patients. Neither of the two
females nor the mother with the deletion had autistic
features at the timeof assessment.However,mildneurocog-
nitive impairment was observed in all three, and one of
them had a history of severe bipolar disorder, and depres-
sion (MIM 608516) was present in another one.
Follow-up Sample
Deletions of 17q12 in ASD/Neurodevelopmental Disorders
We were intrigued to find that six out of the nine patients
we studied in detail had autism or autistic features. We
therefore expanded our assessment of 17q12 deletions to
two independent existing ASD collections. Funded by the
Simons Foundation Autism Research Initiative (SFARI),
the SFARI Simplex Collection (SSC) is a sample of well-phe-622 The American Journal of Human Genetics 87, 618–630, Novembnotyped patients with ASD from families with a single
affected individual. We obtained CNV information, based
on the Illumina 1M SNP array platform, from 806 patients
for this analysis. In this sample, we identified one female
with the 17q12 deletion out of 806 individuals with ASD.
Additionally, we assessed the deCODEneurodevelopmen-
tal collection, composed of 376 patients with ASD and/or
neurocognitive impairment for copy number imbalances
by using Illumina SNP microarrays (317K, 370K, 550K,
1M) as previously described.38 Among this sample, we iden-
tified one female with the 17q12 CNV. To estimate the risk
for the combined ASD/neurocognitive impairment sample,
we used the Cochran-Mantel-Haenszel model because of
the different ethnic compositions of the samples, and we
demonstrated a high risk of ASD associated with this CNV
(Table 2; ORN, 4.73-N, p ¼ 1.92 3 103).
Deletions of 17q12 in Schizophrenia
Having shown the 17q12 deletion to be a strong risk factor
for ASD and intellectual disability, we extended our inves-
tigations to assess the potential role of this CNV in other
neurodevelopmental and psychiatric phenotypes. Given
the genetic and clinical overlap observed between ASD
and schizophrenia,3 we looked for this CNV in two large
existing schizophrenia samples: GAIN and the SGENE
consortium. We obtained and extracted intensities from
the raw data, based on the Affymetrix 6.0 array platform,
of 2167 schizophrenia cases and 2418 controls from
GAIN48 (dbGaP; accession number phs000021.v), where
we identified one female with the deletion among the
cases and no deletions among controls. Additionally, threeer 12, 2010
Table 1. Neurocognitive and Behavioral Phenotype of Nine Patients with 17q12 Deletions
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 Case 8 Case 9 Total
Inheritance de novo de novo de novo de novo U maternal
(son of Case 5)
de novo de novo de novo
Sex female male male male female male female male male
Current age 19 y 4 y 7 y 12 y 37 y 1 y, 9 months 1 y, 10 months 10 y 22 y
Autism or autistic
features
- þ þ þ - þ - þ þ 6/9 in total (66%);
6/6 males (100%);
0/3 females (0%)
Deficits in
coordination and
motor skills
U þ þ þ U þ þ þ þ 7/7 (100%)
Intellectual
impairment
- þ þ þ þ þ þ þ þ 8/9 (89%)
Language
impairment
- þ þ þ - þ þ þ - 6/9 (67%)
Anxiety - - þ þ þ - - þ þ 5/9 (56%)
Aggression - þ - þ - - - - - 2/9 (22%)
Other
behaviors and
neuropsychiatric
comorbidities
depression,
migraines
unusual phobias,
hyperactivity,
short attention
span, extremely
selective diet
occasional
unmotivated
giggling,
extremely
selective diet
mood changes,
obsessive-
compulsive
behaviors
bipolar
disorder
irritability,
minimal
response to pain
- self-injurious
behaviors, pica,
short attention
span
mood changes
Abbreviations: þ, present; -, absent; U, unknown; y, years.
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Figure 2. Facial Phenotype of Patients with 17q12 Deletions
Macrocephaly, epicanthal folds, downslanting palpebral fissures, arched and high eyebrows, slightly depressed nasal bridge, and malar
flattening are the features sharedmost consistently among these patients. Profile pictures and photographs at different ages are provided
when available, showing the progression of the phenotype over time.deletions (two females and one male) out of 4,173 cases
were present in the SGENE collection, assessed via Illumina
SNP microarrays (317K, 370K, 550K, 1M) as described
above, whereas none of the 40,658 controls carried this
imbalance. Again, via the Cochran-Mantel-Haenszel
model to estimate the risk for the combined schizophrenia
follow-up sample, we demonstrated a high risk of schizo-
phrenia associated with deletion 17q12 (Table 2; OR N,
1.25-N, p ¼ 1.47 3 102).Combined Discovery and Follow-up Samples
Overall, this deletion was present in 24 out of the 23,271
patients and in 0 out of the 52,448 controls. All the cytoge-
nomic array platforms we used in this study (Figure S1) can
detect CNVs of much smaller size than this 1.4 Mb dele-
tion, so we do not expect false negative results among
our samples. Likewise, none of the deletions we identified
appear to be mosaic, as we anticipated, given that the
mechanism yielding these imbalances is most probably
nonhomologous allelic recombination, a well-known
meiotic recombination event, as opposed to a mitotic or
somatic event.
We did not have information on the ethnicity for all the
individuals from the ISCA sample; hence, we could not
apply the Cochran-Mantel-Haenszel correction to the
pooled discovery and follow-up samples. However, we
did calculate the uncorrected risk for this combined
sample, which was highly significant (Table 2; OR N,
13.58-N, p ¼ 5 3 1013). We believe this is a useful esti-
mate, and not probably explained by population differ-
ences, for several reasons including the absence of this
CNV from a very large control population, the fact that624 The American Journal of Human Genetics 87, 618–630, Novembmost of the deletions for which we had parental data
were de novo, and the strong penetrance of the deletion
on the phenotype of the patients who have it, albeit
with variable expressivity.Discussion
Initially believed to be one of the few genomic disorders
that spared the central nervous system,46 the 17q12 dele-
tion has been shown to be associated with intellectual
disability or ASD in a few case series.47,49Moreover, a recent
study on patients with ADHD (MIM 143465) identified
one case with the same 17q12 deletion.50 By analyzing
large populations, we now show that this CNV confers
a statistically significant high risk for ASD and schizo-
phrenia. This is important because the 17q12 deletion is
among the 10 most frequent pathogenic recurrent
genomic deletions identified in children with unexplained
neurodevelopmental impairments (E.B.K. et al., unpub-
lished data), with a frequency of 1 in 875 in our clinical
discovery sample and 1 in 1254 in our follow-up sample.
Additionally, this CNV may increase risk for additional
psychiatric conditions such as bipolar disorder. The
17q12 deletion was de novo in all but one of the cases
for whom parents were available for testing; in the only
case in which the deletion was inherited, the mother
with the deletion was affected with bipolar disorder, dia-
betes, and kidney cysts. Taken together with the absence
of this CNV from the 52,448 controls we assessed (Table 2),
this demonstrates the high penetrance of the 17q12 dele-
tion and its etiologic role on the phenotype of these
patients.er 12, 2010
Table 2. Statistical Analyses of 17q12 Deletions in ASD/Neurodevelopmental Disorders and Schizophrenia
Uncorrected Cochran-Mantel-Haenszel
Sample Phenotype
Case Sample
Source
Control
Sample Source Cases Controls OR
95%
CI Lower
95%
CI Upper p OR
95%
CI Lower
95%
CI Upper p
Discovery ASD/
neurodevelopmental
disorders
ISCA Consortium literature (43,44) 18/15,749 0/4,519 N 1.26 N 1.96 3 102
Follow-up ASD/neurodevelopmental
disorders
SSC Chinese SSC Chinese 0/31 0/51
SSC European
American
SSC and GeneSTAR
European American
1/728 0/3,465
SSC Japanese SSC Japanese 0/6 0/31
SSC African
American
SSC and GeneSTAR
African American
0/41 0/1,306
Iceland Iceland 1/376 0/33,645
Overall 2/1,182 0/38,498 N 6.12 N 8.87 3 104 N 4.73 N 1.92 3 103
schizophrenia SGENE Denmark SGENE Denmark 0/565 0/493
SGENE Scotland SGENE Scotland 0/648 0/663
SGENE Germany SGENE Germany 1/1,086 0/1435
SGENE UK SGENE UK 1/91 0/83
SGENE Italy SGENE Italy 0/84 0/86
SGENE Finland A SGENE Finland A 0/126 0/49
SGENE Finland B SGENE Finland B 0/61 0/146
SGENE Holland SGENE Holland 1/613 0/3,687
SGENE Norway SGENE Norway 0/274 0/371
SGENE Iceland SGENE Iceland 0/625 0/33,645
GAIN African
American
GAIN African
American
0/952 0/978
GAIN European
American
GAIN European
American
1/1,215 0/1,440
Overall 4/6,340 0/43,076 N 4.49 N 2.71 3 104 N 1.25 N 1.47 3 102
ASD/
neurodevelopmental
disorders and
schizophrenia
Combined
follow-up
samples
6/7,522 0/47,929 N 7.51 N 6.22 3 106 N 5.99 N 7.37 3 105
Total discovery and
follow up
24/23,271 0/52,448 N 13.58 N 5 3 1013
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Table 3. Recurrent CNVs Identified across ASD and Schizophrenia
Genomic Region Position (Mb)a Size (Mb)a Number of Genesb CNV References
1q21.1 chr1:144,963,732-145,864,377 0.9 7 del 11,12
3q29 chr3:197,244,288-198,830,238 1.6 21 del 13,14
15q13.3 chr15:28,698,632-30,234,007 1.5 6 del 12,15,16
16p11.2 chr16:29,557,553-30,107,434 0.5 25 dup 18,19
16p13.11 chr16:15,421,876-16,200,195 0.8 7 dup 20,21
17q12 chr17:31,893,783-33,277,865 1.4 15 del this study; 49
22q11.2 chr22:17,412,646-19,797,314 2.4 41 del 12,17
a Size and position are calculated in the hg18 genome assembly and exclude the DNA sequence from flanking segmental duplications.
b The number of genes in each region is based on RefSeq coding genes.The 17q12 deletion adds to the growing list of recurrent
CNVs associated with ASD and schizophrenia (Table 3).
Both conditions are characterized by a wide phenotypic
and genetic heterogeneity; however, the same genetic
anomalies are being identified across these different but
related neurodevelopmental diagnoses.3,4 This suggests
that the disruption of the core developmental processes
of the central nervous system can give rise to a wide range
of clinical manifestations, where the final outcome is prob-
ably modulated by the genetic background of each indi-
vidual as well as environmental factors. Interestingly, the
17q12 genomic region overlaps a well-established ASD
linkage peak;51–54 furthermore, an autism association
study55 has implicated genes in this same interval on 17q
(Figure 1). Within our discovery ISCA sample, six of the
nine patients we assessed in detail had autistic features or
autism, and we identified two patients with the deletion
among the independent ASD and neurodevelopmental
samples we analyzed. These observations, along with an
additional report of three patients with the 17q12 deletion
and ASD,49 further strengthen the hypothesis of a major
risk factor for ASD at 17q12. Although none of the patients
with the CNV from the ISCA discovery sample had a diag-
nosis of schizophrenia (probably because of their young
age), we identified four individuals with the 17q12 dele-
tion within the two schizophrenia samples we assessed.
Unlike ASD,56 cytogenomic array testing is not currently
considered a standard of care for patients with schizo-
phrenia. However, this and previous studies show that
pathogenic CNVs that would account for the phenotype
of these patients can be identified in individuals with
schizophrenia.57,58 Independently from the statistical
significance at the population level, the presence of one
of these pathogenic CNVs in a single affected individual
is highly relevant on a clinical basis and could impact
management, as is the case of patients with 22q11 dele-
tions initially ascertained for autism or schizophrenia.
It is unclear why the 17q12 deletion has not been de-
tected previously in large neuropsychiatric samples as-
sessed for CNVs.59–61 One reason could be the presence
of a renal phenotype in several of the patients with this626 The American Journal of Human Genetics 87, 618–630, NovembCNV, which may have caused their exclusion from the
research studies and led clinicians to seek a syndromic
cause for the behavioral impairments. Alternatively, the
population we assessed might be more severely affected
than most ASD and schizophrenia samples, which may
exclude patients with intellectual disability.
In addition to the neurocognitive and behavioral
involvement and a mild but characteristic facial pheno-
type, our patients shared several other phenotypic
features; macrocephaly or relative macrocephaly and doli-
chocephaly were seen across most of the them, suggesting
that 17q12 deletions, along with PTEN (MIM 601728)
mutations, should be considered in the differential diag-
nosis of patients with macrocephaly and ASD, even
though the degree of macrocephaly in the latter is more
severe.62 We also observed mild to moderate intellectual
disability in most of our patients. Although we did find
renal anomalies in our sample, the severity was variable
and generally milder than in patients with the same dele-
tion reported previously; most of our patients had normal
renal function but they may be too young to have devel-
oped a substantial impairment. In a similar fashion, only
the eldest patient (37 years old) had diabetes mellitus,
but careful monitoring of glucose levels for all affected
patients will be important as they age, given their genetic
predisposition. We found malformations of the reproduc-
tive system in two of our patients, including urethral
stenosis in a male (Case 4) and uterus didelphis (Case 1),
as previously described.63–66 Finally, one of the patients
had short stature, which has been observed in other
patients with the 17q12 deletion.47
The co-occurrence ofmultiple, apparently unrelated clin-
ical findings in patients with the 17q12 deletion is sugges-
tive of a contiguous gene syndrome.67 Under this model,
major phenotypic features may be due to haploinsuffi-
ciency of two or more different genes within the deletion.
HNF1B, previously known as TCF2 (transcription factor
2), is responsible for the renal structural abnormalities and
female reproductive tract malformations,64 as shown by
the fact that mutations in this gene cause RCAD, also
referred to as maturity-onset diabetes of the young, type 5er 12, 2010
(MODY5).68 There are no reported neurocognitive or
psychiatric phenotypes in patients with RCAD resulting
from point mutations in HNF1B, although this may not
have been assessed in a systematic fashion. It will be very
important to gather data on a series of patients with
RCAD because of point mutations versus deletion 17q12
to determine the risk of neurocognitive and psychiatric
disorders in these two groups. If patients withHNF1Bmuta-
tions donothaveneurocognitive/psychiatric impairments,
then a different gene within the deleted interval may
account for this component of the phenotype. Point muta-
tions in this other genemay also occur in patientswith idio-
pathic ASDor schizophreniawhodonot have the renal and
endocrine phenotype of HNF1B haploinsufficiency. It is
noteworthy that not all the patients we ascertained with
this CNV resulting from developmental delay or ASD had
a diagnosis of RCAD. However, it is important to refer these
patients for evaluation of renal and endocrine function.
Among the other 14 genes within the deletion, LHX1 is
an interesting candidate to explain the neurocognitive
phenotype. As a potential transcriptional regulator that
plays a role in the differentiation of neural cells and the
transcriptional control of axonal guidance,69 it is expressed
in the brain during early development.69 Additionally, an
Lhx1 knockout mouse model shows that Lhx1 is an essen-
tial regulator of the vertebrate head organizer.70 However,
LHX1 has yet to be associated with disease in humans,
and no single gene deletions, disruptions, or mutations
causing haploinsufficiency have been detected. Future
studies are therefore necessary to identify the gene or genes
responsible for the neurobehavioral phenotype in patients
with the 17q12 deletion.
In conclusion, the current data show that deletion
17q12 is a recurrent pathogenic CNV that confers a very
high risk for ASD, schizophrenia, or neurodevelopmental
disorders. The clinical phenotype of patients with this
deletion, which include macrocephaly, characteristic facial
features, renal cysts, diabetes, neurocognitive impairment,
ASD, and schizophrenia, are suggestive of a contiguous
gene syndrome that extends beyond RCAD. These observa-
tions suggest that haploinsufficiency of 1 of the 15 genes
in the deleted interval has a very high risk of diverse neuro-
cognitive or psychiatric disorders.Supplemental Data
Supplemental Data include phenotypic description of nine
patients with 17q12 deletions in table format, a figure showing
the coverage of the different array platforms used in this study,
and complete lists of consortia members and can be found with
this article online at http://www.cell.com/AJHG/.Acknowledgments
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